Current Clinical Trials

Standard treatment options:

1. Surgical resection: Complete resection of a well-encapsulated, noninvasive thymoma is usually curative and has a risk of local recurrence of less than 2%.[1] In patients with myasthenia gravis, operative mortality can be minimized with close attention to respiratory support when planning surgical treatment.
2. Radiation therapy is not indicated following complete resection of a well-encapsulated thymoma. Radiation therapy should be considered, however, in rare cases when a noninvasive thymoma is incompletely resected, and when the patient is a poor surgical risk.[1]

Check for U.S. clinical trials from NCI's PDQ Cancer Clinical Trials Registry that are now accepting patients with thymoma and thymic carcinoma ¹. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.

General information about clinical trials is also available from the NCI Web site ².

References

1. McKenna WG, Bonomi P, Barnes MM, et al.: Malignancies of the thymus. In: Roth JA, Ruckdeschel JC, Weisenburger TH: Thoracic Oncology. Philadelphia, Pa: WB Saunders Co, 1989, pp 466-477.